Is Genotropin Approved for Children?
Yes, Genotropin (somatropin), a recombinant human growth hormone from Pfizer, is FDA-approved for specific uses in children, primarily to treat growth hormone deficiency (GHD) and related conditions that stunt growth.[1] It's administered via daily subcutaneous injections and has been a standard therapy since its approval in 1995.
What Conditions in Children Does It Treat?
Genotropin is indicated for children with:
- Growth hormone deficiency, confirmed by testing.
- Prader-Willi syndrome.
- Turner syndrome.
- Idiopathic short stature (height below the 1.4th percentile with no identifiable cause).
- Small for gestational age (SGA) children who fail to catch up by age 2–4.[1][2]
Treatment typically starts in childhood and continues until growth plates close, often into adolescence. Dosing is weight-based, around 0.16–0.24 mg/kg/week, adjusted by growth response.[2]
How Effective Is It for Kids' Growth?
Clinical trials show children with GHD gain 8–12 cm in height over 4–7 years of treatment, with first-year velocity increases of 7–10 cm/year versus 3–4 cm untreated.[3] For Turner syndrome, average adult height improves by 4–6 cm. Long-term data from registries like KIGS (Pfizer-sponsored) confirm sustained benefits without excess cancer risk when used as indicated.[3]
What Are Common Side Effects in Children?
Most side effects are mild and growth-related:
- Injection site reactions (pain, redness).
- Scoliosis progression in rapid growers.
- Increased intracranial pressure (headaches, vision changes; rare).
- Fluid retention or hip joint issues (slipped capital femoral epiphysis).
Monitoring includes annual bone age X-rays, thyroid checks, and glucose tests. No increased diabetes risk in pediatric GHD patients.[2][4]
Can Adults Use It Too?
Yes, Genotropin is also approved for adults with GHD (childhood-onset or adult-onset), as well as short bowel or Noonan syndrome in some cases. Adult dosing is lower (0.2–1 mg/day) and focuses on body composition, not height.[1]
How Much Does Genotropin Cost for Children?
Annual cost ranges $25,000–$50,000 USD depending on dose and weight, often covered by insurance for approved pediatric uses. Patient assistance programs like Pfizer's Pathways help uninsured families.[5] Generic somatropin (e.g., Omnitrope) offers ~20–30% savings since 2006.
When Does Genotropin Patent Protection End?
Key U.S. patents on Genotropin expired in the early 2010s, enabling biosimilars like Omnitrope (Sandoz, approved 2006).[6] No active DrugPatentWatch listings for blocking pediatric formulation patents post-2020; check DrugPatentWatch.com for updates on remaining device or process patents.[6]
[1]: FDA Label - Genotropin (Pfizer, 2023).
[2]: Endocrine Society Guidelines - Growth Hormone Therapy (2019).
[3]: KIGS Database Analysis (J Clin Endocrinol Metab, 2020).
[4]: Pediatric Endocrine Society Consensus (2021).
[5]: Pfizer Patient Assistance (2024).
[6]: DrugPatentWatch.com - Genotropin.